Kiss Peptide: before the kiss
Hormone pulses. Desire. The distance between a biological signal and a human feeling.
A romantic name, an unromantic beginning
Romance was my first association with kisspeptin. Its history starts somewhere much less coy: KISS1 emerged from melanoma research, before the GPR54 puberty findings established how essential its signaling is to reproductive development. The name seems to have arrived ready for a love story; the biology took a different route.
Kisspeptin is a peptide, a short chain of the amino-acid building blocks found in proteins. It can prompt the hormone system that governs reproduction. PT-141, also called bremelanotide, acts through a different receptor family in the brain. Its human trials measured sexual desire and distress about low desire. Both belong here because the ordinary word kiss brings those subjects close together. The experiments still have to tell them apart.
I had mentally filed kisspeptin under hormones and PT-141 under wanting. That filing was too neat. A hormone response can fade while exposure continues; an animal reward experiment can return a negative result for a drug with positive human desire trials. Those are the awkward turns that make this subject interesting to me.
The IVF trigger and the uncooperative hamster
For kisspeptin, I rate the IVF trial in women at high risk of ovarian hyperstimulation above the sweeping libido reputation. Oocyte maturation occurred in 95% of the 60 participants, with no moderate, severe or critical ovarian hyperstimulation syndrome. That is a concrete result in a closely supervised fertility setting. It deserves attention on those terms.
My PT-141 starting point is less flattering: bremelanotide did not enhance sexual reward in female Syrian hamsters in a conditioned place preference experiment. This does not undo the human trials. It does unsettle the appealing idea of a single switch for wanting, pleasure and everything that follows.
The clinical-status review of kisspeptin records an investigational compound with no approved product. The bremelanotide prescribing information describes an approved injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Those are very different positions.
Where the story goes next
Kisspeptin and KISS1R follows the discovery into puberty, interrupted hormone pulses, IVF and the laboratory tools that share its name. PT-141 follows a desire score into the scanner and then into that inconvenient animal result.
The kisspeptin vs PT-141 comparison puts the study populations beside each other. The questions page deals with testosterone, approval and the recurring question about taking them together.
Precision is my test of a result, even if it sounds less romantic afterwards. A kiss can remain an ordinary human mystery. These papers have narrower work to do.